Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: diabetes/obesity therapy - Celera Genomics

Drug Profile

Research programme: diabetes/obesity therapy - Celera Genomics

Latest Information Update: 04 Oct 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celera Genomics Group
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetes mellitus; Obesity

Most Recent Events

  • 25 Jan 2006 Discontinued - Preclinical for Diabetes mellitus in USA (unspecified route)
  • 25 Jan 2006 Discontinued - Preclinical for Obesity in USA (unspecified route)
  • 02 Nov 2005 The programme is available for partnership (http://www.celera.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top